L’ère de l’homme bionique
Article publié sur Allnews
By Salima Barragan
Selon Katherine Taglieri d'AtonRâ, le marché de la médecine bionique pèse 130 milliards de dollars.
Exosquelettes, yeux et oreilles bioniques: l’ère de l’homme augmenté a sonné. La médecine bionique, fusion entre la biologie, l’électronique et la mécanique, est en plein essor. «L’homme qui valait 3 milliards», la série télévisée des années 1970, relève-t-elle encore de la fiction? Pour l’instant, la bionique n’est pas destinée aux superhéros, mais elle vise à restaurer ou améliorer les fonctions de l'organisme des patients. Selon AtonRâ, elle s’adresse à un marché de 130 milliards de dollars. Le point sur les organes artificiels avec Katherine Taglieri, ingénieure biomédical.
En 2013, Bertolt Meyer avait démontré avec Franck, son prototype d’homme bionique, que 60 à 70% des fonctionnalités du corps humain pouvaient être exécutées artificiellement. Six ans plus tard, certains organes (comme le système digestif, le foie et le cerveau) n’ont toujours pas été reproduits et d’autres, déjà commercialisés comme les yeux bioniques, ne sont pas encore au point. «La vision est en noir et blanc et la résolution est très basse; l’on ne distingue que les gros objets», nous prévient Katherine Taglieri.
Explore:
Disclaimer
This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.
As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.
Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.
It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.
Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.
Back to research
